Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quilizumab in refractory chronic spontaneous urticaria
2013-003233-15Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Quilizumab with Placebo (2 arms). Primary endpoint: Improvement in itch score. Started Oct 2013; status: completed.
02
Drugs
quilizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2013-003233-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003233-15.